Search Results
Oct 14, 2025, 10:00 ET Everbright Health Launches with $7M Investment and 75 Provider Partners to Expand Access to Advanced Mental Health Interventions
psychiatric interventions are on the cusp of becoming mainstream care. With remarkable outcomes, we believe they are poised to have their own 'GLP-1' moment for market adoption." About Everbright Everbright
More news about: Everbright Health
Oct 14, 2025, 08:31 ET MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing
More news about: MetaVia Inc.
Oct 14, 2025, 08:00 ET Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
Abstract Title: Oral Controlled-Metabolic Accelerator Drives Fat-Specific Weight Loss and Augments GLP-1 EffectAbstract Number: 121Format: Poster PresentationPresenter: Sol Collado, Ph.D., Senior Director,
More news about: Rivus Pharmaceuticals
Oct 14, 2025, 06:00 ET 歌禮與中國國家藥品監督管理局完成地尼法司他（ASC40）的新藥上市申請前溝通
研 小分子 GLP-1 受體 （ GLP-1R ） 激 動劑
More news about: 歌禮製藥有限公司
Oct 14, 2025, 06:00 ET Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy
More news about: Ascletis Pharma Inc.
Oct 14, 2025, 06:00 ET Twin Health and Peloton Partner to Transform Metabolic Health
content. Together, we help members achieve lasting health outcomes and sustain muscle mass while safely reducing or discontinuing costly medications like GLP-1s, without rebound weight gain." This comes on the heels of the release of a landmark
More news about: Twin Health
Oct 13, 2025, 17:16 ET Healing Healthcare: Specialdocs Inspires Change at the 2025 Concierge Medicine Forum
seamless grand opening. Weight Loss Management in the GLP-1 Era: A concierge medicine approach to success. Map Your Route to Concierge
More news about: Specialdocs Consultants
Oct 13, 2025, 08:46 ET Fresh Thyme Market Reveals 2026 Food Trend Forecast
Neuro Gum Focus Gummies 10. GLP-1 Lifestyle Support: With the rise of GLP-1 medications, shoppers are prioritizing nutrient-rich foods that support metabolism, satiety, and balanced nutrition.
More news about: Fresh Thyme
Oct 12, 2025, 20:10 ET Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
respectively. - ASC35 was approximately 4-fold more potent than tirzepatide for both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) in vitro. - ASC35 demonstrated
More news about: Ascletis Pharma Inc.
Oct 11, 2025, 08:45 ET C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
IND filing to clinical and commercial supply. Headquartered in Chengdu Medical City, C-Ray operates a 28,000 m² world-class GMP facility and GLP-like nonclinical research center. With more than 50 projects delivered and ongoing, C-Ray is building an open innovation platform to accelerate theranostic
More news about: C Ray Therapeutics
Oct 10, 2025, 09:10 ET Parker Waichman LLP Investigates Vision Loss Cases Linked to Ozempic and Other Semaglutide Drugs Following EMA Confirmation of NAION Risk
should be discontinued if NAION is confirmed." This finding adds to growing global concern regarding the safety of GLP-1 receptor agonist medications, including Ozempic and Wegovy, which were originally developed to treat Type 2 diabetes but are now widely prescribed
More news about: Parker Waichman LLP
Oct 09, 2025, 10:11 ET Mintel Announces 2026 Food and Drink Predictions
explorations of how to formulate for the unique sensory needs of underserved consumer groups, including the elderly, neurodiverse individuals or GLP-1 medication users, while remaining enticing to mainstream consumers. "Brands have an opportunity not just to reimagine traditional
More news about: Mintel Group, Ltd.
Oct 09, 2025, 10:01 ET Cardiovascular Drugs Market to 2030: APAC Leads Growth and Telehealth Helps Online Pharmacies Expand, Says Mordor Intelligence
New drug classes are reshaping treatment pathways. NOACs are rapidly replacing warfarin, while SGLT2 inhibitors and GLP-1 agonists extend beyond diabetes to heart-failure care and risk reduction, opening new market segments.
More news about: Mordor Intelligence Private Limited
Oct 09, 2025, 10:00 ET FYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform and Accelerate Breakthroughs in Precision Medicine
consistent, repeatable results. With Fuzzball, workflows can be preserved and rerun exactly as originally executed, providing the confidence needed for GLP, GXP, and FDA-regulated environments, without sacrificing speed or quality. Strategic Value: Pharma
More news about: CIQ
Oct 09, 2025, 09:05 ET Parker Waichman LLP Files Lawsuit on behalf of Florida Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
Oct 09, 2025, 08:00 ET Cirius Therapeutics to Participate in Upcoming Healthcare Conferences
to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the synergistic transformation of subcutaneous
More news about: Cirius Therapeutics
Oct 09, 2025, 07:07 ET Simple Life raises $35M Series B to scale its AI health coach for lasting weight loss
behavior change with continuous coaching and real‑time nutrition to deliver durable weight outcomes and a healthier metabolic profile, with or without GLP‑1s. Proof of impact Simple's AI coach ("Avo"), named MedTech Breakthrough's
More news about: Simple Life
Oct 08, 2025, 12:15 ET Shed Launches Community Platform to Reinvent Support for Sustainable Weight Loss
GLP-1s or focusing on sustainable lifestyle changes, the platform is designed to provide daily momentum—through a supportive, private community that fosters
More news about: Shed
Oct 08, 2025, 10:00 ET GenoPalate Advances Its Science Again With Diet Snapshot
supplement plans that fit each member's routine. Programs align with primary health concerns, including weight management without medication, GLP-1 support, perimenopause and menopause support, healthy aging, and targeted supplementation. When prescription support is appropriate, GenoPalate's
More news about: GenoPalate
Oct 07, 2025, 17:30 ET BIOVAXYS ANNOUNCES LIFE OFFERING
solutions can address specific needs or gaps, making the Company an attractive 'go-to' partner for targeted immunotherapies; (2) identifying remaining GLP supply or production of (non-GMP) preclinical supply of DPX to be used in conducting research, preclinical supply of DPX+peanut antigen for the peanut
More news about: BioVaxys Technology Corp.
Oct 07, 2025, 12:00 ET Beacon Wellness Brands Partners With Midi Health to Launch Menopause Benefits for Employees
clinicians specializing in midlife women's health Personalized prescriptions and care plans, including HRT and GLP-1 options Referrals for advanced care related to menopause and perimenopause
More news about: Beacon Wellness Brands
Oct 07, 2025, 08:34 ET GeneVentiv Therapeutics Selected into NHLBI Catalyze Program to Fund IND-Enabling Toxicology Study for GENV-HEM
Heart, Lung, and Blood Institute (NHLBI). Through this program, NIH will fund and provide preclinical services with leading national providers for the GLP toxicology study required for the company's IND submission of GENV-HEM, its investigational one-time gene therapy for hemophilia A, including patients
More news about: GeneVentiv Therapeutics
Oct 07, 2025, 08:00 ET Foodsmart Expands Executive Team with Technology, Customer Experience, and Finance Leaders to Advance Foodcare Nationwide
analysis of GLP-1 users found that members receiving GLP-1 + Foodsmart combination therapy achieved $168 PMPM in total net savings—including $43 PMPM in medical savings and $125 PMPM in pharmacy savings—compared to members on GLP-1s alone.
More news about: Foodsmart
Oct 06, 2025, 08:00 ET Lipidio Pharmaceuticals Expands Advisory Team with Appointment of Renowned Experts Arne Astrup, MD and Mark Lappe
scientific achievements, Professor Astrup co-discovered with Professor Jens Holst in 1996 that GLP-1 is a satiety hormone in humans—a discovery that underpins the use of GLP-1 agonists as obesity and diabetes therapies. He also played a pivotal role in Denmark's 2004 ban on industrially
More news about: Lipidio Pharmaceuticals, Inc.
Oct 03, 2025, 08:38 ET Novo Nordisk: Novo estudo com Wegovy® revela perda de gordura visceral com preservação da força muscular
percentil 95 ou superior para a idade e gênero (obesidade) e peso corporal acima de 60 kg. Trata-se do primeiro análogo semanal do GLP-1 aprovado pela Agência Nacional de Vigilância Sanitária (Anvisa) para tratar pessoas que vivem com obesidade e sobrepeso com ao menos uma comorbidade
More news about: Novo Nordisk